Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 15, 2019

Tracon ends TAPPAS trial of TRC105 in angiosarcoma

Tracon Pharmaceuticals has terminated the Phase III TAPPAS clinical trial conducted to assess TRC105 plus Votrient (pazopanib) in advanced or metastatic angiosarcoma patients.

Tracon Pharmaceuticals has terminated the Phase III TAPPAS clinical trial conducted to assess TRC105 plus Votrient (pazopanib) in advanced or metastatic angiosarcoma patients.

The move comes after a review by the Independent Data Monitoring Committee (IDMC) found that the combination did not lead to clinically meaningful efficacy.

The IDMC analysed interim unblinded safety and efficacy findings from more than 120 participants.

TRC105 is an oncology formulation of carotuximab and an antibody to the endoglin protein, which is overexpressed on proliferating endothelial cells required for the formation of new blood vessels.

“We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy.”

TAPPAS was intended to evaluate TRC105 in combination with Votrient, compared to Votrient alone, in a total of 340 subjects. Tracon started dosing patients in the trial in February 2017.

The trial’s primary endpoint was progression-free survival. Its secondary endpoints included objective response rate, safety, overall survival, and tolerability.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Based on the TAPPAS results, the company has decided to terminate further enrolment into its trials of TRC105 in oncology indications.

Tracon Pharmaceuticals president and CEO Charles Theuer said: “We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy in patients with advanced or metastatic angiosarcoma.

“On a financial note, as a result of the expected savings to be generated from terminating TRACON sponsored trials of TRC105, we anticipate our current cash runway will now extend into the third quarter of 2020.”

Under a licence to Santen Pharmaceutical, Tracon is also developing an ophthalmic formulation of TRC105, called DE-122, for the treatment of wet age-related macular degeneration.

DE-122 is currently in Phase II AVANTE trial for wet AMD patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU